Navigation Links
AnaptysBio Announces Appointment Of James A. Schoeneck To Board Of Directors
Date:11/19/2015

SAN DIEGO, Calif., Nov. 19, 2015 /PRNewswire/ -- AnaptysBio, Inc., a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology, today announced the appointment of James A. Schoeneck to its Board of Directors. 

"We are thrilled to welcome Jim to AnaptysBio's Board of Directors," said Hamza Suria, President & CEO of AnaptysBio. "Jim brings a strong track-record in building biotechnology companies and commercialization of therapeutic products. His experience is highly relevant for AnaptysBio's strategic vision to advance our anti-IL-33 antibody program to multiple clinical proof-of-concept studies and develop our anti-IL-36 receptor antibody to market launch in orphan inflammatory conditions."

Mr. Schoeneck said, "I am pleased to join AnaptysBio's Board of Directors and work closely with the company's accomplished leadership team. AnaptysBio's antibody pipeline is at the forefront of new therapeutic opportunities in inflammation and immuno-oncology. The company's validated technology platform and product development capabilities provide us a unique opportunity to rapidly advance antibody product candidates for emerging biological targets."

Mr. Schoeneck is currently President & CEO of Depomed, a publicly traded specialty pharmaceutical company. Prior to joining Depomed in 2011, Mr. Schoeneck was CEO of BrainCells Inc., ActivX BioSciences and Prometheus Laboratories Inc. Prior to Prometheus, Mr. Schoeneck led the development of Centocor's commercial capabilities, including the market launch of Remicade®, which has become one of the most successful therapeutic antibodies in history.  Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi-Aventis) serving in various sales and marketing positions of increasing responsibility. Mr. Schoeneck holds a B.S. degree in Education from Jacksonville State University.

About AnaptysBio

AnaptysBio is an antibody development company focused on novel programs in inflammation and immuno-oncology. The Company's proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and severe adult peanut allergy, and ANB019, an anti-IL-36 receptor antibody initially being developed for the treatment of generalized pustular psoriasis. AnaptysBio's SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery, which is designed to replicate key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Celgene and TESARO.

Contacts:
Julie Rathbun
julie@rathbuncomm.com  
206-769-9219

Logo - http://photos.prnewswire.com/prnh/20111205/SF16052LOGO

 


'/>"/>
SOURCE AnaptysBio
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease
2. Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibody Program from AnaptysBio
3. New On NineSights: NineSigma Announces The Newest Opportunities for Innovators
4. Memgen Announces Preclinical Results for Its ISF35 Cancer Immunotherapy with Checkpoint Inhibitors in Metastatic Melanoma
5. Cirrascale® Announces Premier Deep Learning 4U Rackmount Server Supporting 10 PCIe Gen3 Devices with Support for NVIDIA® Tesla® Accelerated Computing Platform
6. Svigals+Partners Announces Completion of Innovative Facility for Children’s Brain Research at UConn
7. BioAmber Announces Hiring of Chief Financial Officer
8. Pittcon 2016 Announces Topics for Conferee Networking Sessions
9. Neurotrope, Inc. Announces $15.3 million Private Placement
10. Aeterna Zentaris Announces Exercise of Series B Warrants
11. The Genome Analysis Centre Announces an Important Milestone in Wheat Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... ... August 29, 2020 , ... DuPont ... capability in Wuxi, China. The new plant operation will provide the local animal ... technology. , “This facility will improve the flexibility of our offerings to ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... chain validation engineering firm, is making available for free its new white ... incorporate concurrent transport simulation testing into today’s biologics licensing application (BLA). In ...
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – MediVet ... , Known as MediVet Biologics since its formation in 2016, the ... new Ardent Animal Health will build on its base of innovative therapies for osteoarthritis ...
(Date:7/31/2020)... ... 29, 2020 , ... Anomet Products has introduced new custom ... use with CRM, neurostimulation, vascular, and related devices. , Anomet Medical Clad ... performance, and cost criteria; especially where solid wire is limited. Typical configurations for ...
Breaking Biology Technology:
(Date:7/10/2020)... (PRWEB) , ... July 08, 2020 , ... ... on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 ... a comparability study, but what is the most effective way to complete one? ...
(Date:7/1/2020)... , ... July 01, 2020 , ... ... it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located ... existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... antibody development services, today announced that the company has received ISO9001:2015 certification ... pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation demonstrates ...
Breaking Biology News(10 mins):